Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.50.

Several research analysts have recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday. Lake Street Capital raised Alphatec to a “buy” rating and set a $18.00 price objective for the company in a research report on Monday, June 16th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Friday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th.

Insider Transactions at Alphatec

In other Alphatec news, Director Karen K. Mcginnis sold 3,963 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $12.11, for a total transaction of $47,991.93. Following the completion of the sale, the director directly owned 68,709 shares of the company’s stock, valued at approximately $832,065.99. The trade was a 5.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Craig E. Hunsaker sold 10,876 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $15.33, for a total value of $166,729.08. Following the sale, the executive vice president directly owned 1,389,142 shares of the company’s stock, valued at $21,295,546.86. This represents a 0.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 449,997 shares of company stock valued at $5,846,616. 22.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Alphatec

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in Alphatec by 38,433.3% during the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock worth $228,000 after purchasing an additional 2,306 shares in the last quarter. Comerica Bank increased its holdings in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares in the last quarter. Larson Financial Group LLC bought a new stake in Alphatec during the 1st quarter worth approximately $54,000. Quarry LP increased its holdings in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares during the last quarter. 66.35% of the stock is owned by institutional investors.

Alphatec Stock Up 0.5%

Shares of ATEC opened at $14.97 on Monday. The company has a market capitalization of $2.22 billion, a PE ratio of -13.25 and a beta of 1.05. Alphatec has a 12 month low of $4.88 and a 12 month high of $15.46. The stock’s 50-day moving average price is $11.63 and its two-hundred day moving average price is $11.28. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The firm had revenue of $185.54 million during the quarter, compared to analyst estimates of $178.85 million. During the same period last year, the company posted ($0.29) EPS. The business’s quarterly revenue was up 27.5% on a year-over-year basis. On average, analysts anticipate that Alphatec will post -1.08 EPS for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.